The pTEN/AKT/mTOR signaling pathways play a critical role in balancing cell proliferation, differentiation, and survival. Recent studies researched the associations of core genes in the pTEN/AKT/ mTOR pathway polymorphisms with the cancer susceptibility; however, the results are inconclusive. Therefore, a systematically meta-analysis was performed to evaluate the association between the five SNPs (mTOR rs2295080 and rs2536, AKT1 rs2494750 and rs2494752, pTEN rs701848 . The carcinogenesis is involved in multifactor interaction among environmental exposures, life style and internal factors. In terms of internal factors, the main manifestations are changes in hormone secretion and immune conditions, and genetic variation in the key signaling pathway. In humans, the phosphatase and tensin homolog deleted on chromosome10 (pTEN)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in a variety of cancers, and play a critical role in many cellular processes including proliferation, differentiation, cell cycle progression, cell motility and tumorigenesis, tumor growth, angiogenesis [3] [4] [5] . Therefore, the Single nucleotide polymorphisms (SNPs) of core genes in the pTEN/AKT/mTOR pathway may impact the transcription and expression of the proteins and thus alter the capacity and function of the pathway, which could play a critical role in carcinogenesis [6] [7] [8] [9] . The mTOR, which is located at the chromosome 1q36.2, plays a significant role in the pTEN/AKT/mTOR pathway. It exerts a prosurvival influence on cells through the activation of factors involved in protein synthesis [10] [11] [12] [13] . pTEN is a tumor suppressor and plasma-membrane lipid phosphatase and which dephosphorylates PIP3 
to PIP2, inhibiting the activation of AKT, and negatively regulates the pTEN/AKT/mTOR pathway 14 . To date, among the pTEN/AKT/mTOR pathway genes, there are more than 1000 coding-region SNPs (cSNPs) (http:// www.ncbi.nlm.nih.gov/projects/SNP) reported. Among those cSNPs, a few potential functional SNPs especially located in the 5′-untranslated regions(5′UTR) and 3′UTR of the candidate genes could affect the carcinogenesis by modulating the transcriptional activity of candidate genes or by interacting with the miRNA binding, such as rs2295080 in the mTOR gene promoter region [15] [16] [17] [18] [19] [20] [21] [22] [23] , rs2494750 and rs2494752 in the AKT1 5′UTR region 7, 15, [23] [24] [25] [26] [27] , rs2536 in the 3′UTR of mTOR 7, [15] [16] [17] [18] 22, 23, [28] [29] [30] and rs701848 the pTEN 3′UTR region 7, 15, 27, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Furthermore, previous studies demonstrated that the mTOR rs2295080 TT genotypes carriers showed a much higher mRNA levels of mTOR transcription by increasing the transcriptional activity of mTOR gene in human gastric cancer cell line SGC-7901 6 . Moreover, carrying the rs2295080 T allele showed increased mTOR mRNA levels compared with the G allele in the patients with renal cell cancer 7 and colorectal cancer 8 . Moreover, another SNP rs2536 located in the mTOR 3′-UTR was predicted to affect miRNA-binding site activity. Li et al. 43 found that co-transfection of the rs2536 A allele and G allele with miR-767-3p exhibited different promoter activities. Additionally, the polymorphism of pTEN rs701848 was proposed to involve in affecting the activity of micorRNA binding site 36 . Therefore, considering the critical role of the genetic variations in the pTEN/AKT/mTOR pathway, understanding the association between these SNPs and cancer susceptibility are urgently required.
To date, numerous studies have investigated the association of genetic polymorphisms of pTEN/AKT/mTOR pathway genes including rs2295080, rs2536 of mTOR gene, rs2494750 and rs2494752 in the AKT1 gene, pTEN rs701848 with cancer susceptibility [6] [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] [22] [23] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , however, the results were inconclusive. Therefore, this comprehensive meta-analysis was performed in 5 SNPs of pTEN/AKT/mTOR pathway genes included all eligible case-control studies for evaluating the cancer risk and providing more precise estimation of these associations.
Materials and Methods
Literature research and data extraction. A comprehensive literature search was performed independently by three authors (Z.Z., J.Z., and Q.C.C.) in five electronic databases: PubMed database, CNKI, CbmWeb, WanFang Date, BIOSIS Preview, and ClinicalKey. All the searched eligible original studies and review articles were reviewed carefully to identify the relevant articles by using the following search terms "mTOR rs2295080" or "mTOR rs2536" or "pTEN rs701848" or "AKT1 rs2494750" or "AKT1 rs2494752" and "polymorphism or SNP or single nucleotide polymorphism or variation or mutation" and "cancer or carcinoma or tumor or neoplasm", (the search was updated on Feb 15, 2017) . This search was limited to these articles with English or Chinese language, and the results were reviewed and compared by a forth reviewer (Y. L.W.).
In this meta-analysis, selected publications were eligible if they fulfilled the following criteria: (1) a case-control study or cohort study design; (2) evaluated the association of the genetic polymorphisms of mTOR, AKT1, and pTEN gene with the risk of cancer; (3) sufficient genotypic and/or allelic information for estimating the odds ratio (OR) with 95% confidence intervals (CIs) was provided; (4) the samples size of cases or controls were ≥20. Animal studies, case reports, reviews, and unpublished results were excluded. The following data was extracted from each publication in the collection criterion by Z.Z. and Y. L.W. independently: first author, publication year, ethnicity, country, cancer type, control source (population-based controls, or hospital-based controls), genotyping method, the total number of genotyped cases or controls, and the number of each genotype for cases and controls with each SNP for cancer risk assessment.
Statistical analysis.
For the genotype frequency of the controls, the Hardy-Weinberg equilibrium (HWE) was assessed by using the Chi-square test or Fisher's exact test (P > 0.05) in each study. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were estimated to evaluate the strength of association between these selected 5 SNPs and cancer risk. The pooled estimated ORs and CIs were determined by Z-test based on homozygote model, heterozygote model, dominant model, recessive model, and an additive model(significant for P < 0.05). The heterogeneity between-study was assessed across all eligible comparisons by using χ 2 -based Cochran's Q-test (significant for P < 0.10). The random-effects model (DerSimonian-Laird method) was chosen If there is statistical heterogeneity, otherwise the fixed-effects model (Mantel-Haenszel method) was used if the studies were homogeneous. The I 2 statistics was also determined from 0% to 100%, which quantified the heterogeneity irrespective of the number of studies. The sensitivity meta-analysis was assessed by leave-one-out each time to reflect the influence of each study to the pooled estimates. The publication bias was evaluated by the Egger's and Begg-Matzumdar linear regression tests using asymmetry of the funnel plot (significant for P < 0.10). All the statistical analyses of this meta-analysis were performed by using Stata 12.0 software (StataCorp LP, College Station, USA) and Open Meta-Analyst (http://www.cebm.brown.edu/openmeta/).
Results
Studies extraction and characteristics. Figure 1 summarizes a flowchart presenting the literature review process of study identification, inclusion, exclusion. With the search strategy, a total of 145 published articles were extracted and identified for cancer risk assessment from PubMed, CNKI, CbmWeb, WanFang Date, BIOSIS Preview. After manually screening abstracts and texts of the included 145 studies, 114 were excluded for 2 lack of enough information, 14 abstracts without sufficient data, and 98 duplicated publication or overlapping with other publications for further evaluation. Finally, 31 studies of Asian population were met the inclusion criteria [6] [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] [22] [23] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , 13 studies of them evaluated the association of mTOR rs2295080 with cancer risks [6] [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] [22] [23] , 10 studies determined the SNP rs2536 of mTOR gene and cancer susceptibility 7, [15] [16] [17] [18] 22, 23, [28] [29] [30] , 16 publications were pTEN rs701848 polymorphism 7, 15, 27, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , 6 reports studied the AKT1 rs2494750 SNP 7,15,23-27 and 3 reports determined AKT1 rs2494752 SNP 19, 26, 27 . The distribution of genotypes in the controls for the SNPs of pTEN/AKT/ mTOR pathway were in the HWE, except for these 2 publications of Liu, B et al. 33 for rs70148 and Fallah et al. 24 for rs2494750 ( Figure S1 . Overall, we observed that carrying mTOR rs2295080 TG or GG genotype and GG/TG genotype showed significant association with decreased cancer risk [TG vs .TT in heterozygote model: OR(95% CI) = 0.82(0.76, 0.89), P < 0.001; GG/TG vs. TT in dominant model: OR(95% CI) = 0.82(0.76, 0.88), P < 0.001; and GG vs.TG/TT in recessive model: OR(95% CI) = 0.67(0.51, 0.88), P = 0.004]. In view of the relative higher heterogeneities, we further analyzed the data by stratification subgroups of urinary system cancer, blood system cancer, and digestive system cancer. Subsequently, we found that rs2295080 GG genotype, TG genotype, and GG/TG genotypes carriers showed a significantly decreased cancer risk in the stratification analysis of urinary system cancer [GG vs However, in the subgroup analysis of blood system cancer, inversely results were found that a significantly increased cancer risk was observed in the carriers of GG genotype [GG vs.TT: OR(95% CI) = 2.25(1.33, 3.82), P = 0.003]. For mTOR rs2536 polymorphism, there was no association was observed both in overall analysis and subgroup analysis (Tables 2 and 3) . pTEN rs701848 and cancer risk analysis. The effect of pTEN rs701848 polymorphism on cancer risk in overall and subgroup analysis was shown in Tables 2, 3 AKT1 rs2494750, rs2494752 and cancer risk analysis. The association between polymorphisms of AKT1 rs2494750, rs2494752 and cancer risk in overall meta-analysis results was shown in Tables 2, 3 and Fig. 3 , and Figure S2 . A significant association was observed between AKT1 rs2494752 and overall cancer risk, and the heterozygous genotype AG and GG/AG genotype of AKT1 rs2494752 were associated with increased cancer risk (AG vs. AA in heterozygote model: OR(95% CI) = 1.13(1.01, 1.25), P = 0.026; and GG/AG vs. AA in dominant model: OR(95% CI) = 1.13(1.02, 1.25), P = 0.017). For AKT1 rs2494750 polymorphism, we have not found the correlation with the cancer susceptibility both in overall analysis and subgroup analysis (Tables 2 and 3 ).
Heterogeneity and sensitivity analysis. No significant heterogeneities were observed for the overall analyses of mTOR rs2536, AKT1 rs2494750 and rs2494752. However, the highest heterogeneity were observed when all the studies were analyzed for all the cases of mTOR rs2295080 under the dominant model (I 2 = 96.1%) (Tables S1 and S2 ). The heterogeneity of mTOR rs2295080 was also present in the subgroup of urinary system cancer and digestive system cancer under the dominant model (Table S2) . Therefore, the leave-one-out sensitivity analysis and random-effects model was selected for decreasing the heterogeneity. 2015) from digestive system cancer, the subgroup of heterogeneity significantly decreased from 97.6% to 0% (Tables 3 and S2 ). Another article of Zhu, J.H. (2015) from urinary system cancer was deleted, the I 2 decreased from 96.3% to 0% under the dominant model in subgroup analysis (Tables 3 and S2) . For pTEN rs701848, we found that the heterogeneity of overall and subgroup was significantly decreased after deleting this article of Zhang Y.G.(2014), except the subgroup under the digestive system cancer (Tables 2, 3 , S1 and S2). Publication bias analysis. In this meta-analysis, the Begg's funnel plot and Egger's test were performed to evaluate the publication bias of the concluded studies. There are no significant publication bias was observed for all the dominant models of the five SNPs (rs2295080: P = 0.200; rs2536: P = 0.176; rs701848: P = 0.218; rs2494750: P = 0.694 and rs2494752: P = 0.696) by the Egger's test. The funnel plots shapes showed obvious symmetry, which were obtained for the association of the SNPs under the dominant model (rs2295080: P = 0.672; rs2536: P = 0.531; rs701848: P = 0.373; rs2494750: P = 1.000 and rs2494752: P = 602) (Fig. 4) . The data indicated that no publication bias might have a significant influence on the observed effect of SNPs located at pTEN/AKT/ mTOR pathway on the susceptibility of cancer as assessed.
Discussion
Overexpression or mutations of key genes of the pTEN/AKT/mTOR pathways were associated with carcinogenesis, invasion, metastasis, and prognosis of a variety of cancers 44, 45 . Since one group investigated the association of genetic polymorphisms of the pTEN/AKT/mTOR pathway with cancer risk for the first time 31 , a variety of studies have been performed to explore the possible correlation of the SNPs in this pathway genes on cancer susceptibility [6] [7] [8] [9] [15] [16] [17] [18] [19] [20] [21] [22] [23] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . The potentially functional SNPs in those key genes, especially in the TFBS or miRNA binding sites may involve in the cancer susceptibility. Therefore, the present meta-analysis analyzed the associations of SNPs in the 5′upstream regulatory or promoter region (mTOR rs2295080, AKT1 rs2494752), and 3′UTR region (mTOR rs2536, pTEN rs701848 and AKT1 rs2494750) in the mTOR signaling pathway (AKT, and PTEN) with cancer risk. mTOR rs2295080 and rs2536 SNPs and cancer risk. Given the crucial function of mTOR in cellular signals from growth factors and energy status, such as in angiogenesis and cell proliferation, growth, differentiation, and apoptosis [3] [4] [5] 44, 45 , our findings of an association between the genetic variations in mTOR gene and cancer risk are biologically plausible and wide, including renal cell cancer 7, 21, 23 , prostate cancer 15, 17 , breast cancer 22 , acute 8 . In this meta-analysis of 13 studies including 8965 cases and 9868 controls for rs2295080, we found a significant decreased of rs2295080 TG, GG genotype, G allele and TG/GG genotype on the overall cancer risk, and the stratification subtype of urinary system cancer and digestive system cancer. However, a significant increased association was found on the blood system cancer in the homozygous GG genotype and G allele under the subgroup analysis. Up to now, only two meta-analyses focused on mTOR rs2295080 polymorphism and cancer risk 46, 47 . In one meta-analysis reported that the rs2295080 G allele is associated with decreased risk of cancer 46 , however, only five studies were included. Recent some opposite findings were reported in gastric cancer 6 , esophageal cancer 18 , and especially in acute leukemia 16, 20 . Thereafter, another eight studies meta-analysis found that the rs2295080 G allele was associated with a significantly lower risk of genitourinary cancers in the dominant model, and a higher risk of acute leukemia in the recessive model 47 , which consistent with our founding's in overall cancer risk and digestive system cancer. Likewise, we further founded that carrying rs2295080 GG genotype showed increased 2.25-fold association in the blood system cancer including acute lymphocytic leukemia and acute lymphocytic leukemia which was not explicated in the previous meta-analyses. Thus, these data indicated that there was an obvious divergence between the SNP rs2295080 and cancer risk in the digestive system and blood system, which might be partially explained by cancer-specificity of rs2295080 polymorphism.
10 studied of 8411 cases and 8837 controls for rs2536 polymorphism, no significant association was observed between rs2536 and cancer susceptibility after performing stratified analyses by cancer type 7, [15] [16] [17] [18] 22, 23, [28] [29] [30] in this pooled meta-analysis. Previously, Shao et al. 46 performed a six case-control studies meta-analysis and also reported that there was no association of rs2536 SNP with cancer risk both under dominant and recessive models. Furthermore, this present updated meta-analysis also indicated that rs2536 polymorphism was not an important biomarker for predicting cancer risk, although rs2536 was observed associated with the risk of esophageal cancer 18 and prostate cancer 15 , together with interacting with environmental factors such as body mass index. The previous foundlings were controversial for the SNP rs2536, partially because of insufficient statistical power and further studies of different cancers are needed for providing a more precise estimation of the associations. pTEN rs701848 and cancer risk. pTEN was originally identified as tumor suppressor gene, considered as a key negative regulator of PI3K/Akt pathway [48] [49] [50] . However, little is known about the association between pTEN rs701848 polymorphism and cancer. Specifically, 15 studies of 5882 cases and 6284 controls for rs701848, CC or TC genotype, C allele and CC/TC genotype were associated with significant increased overall cancer risk and in the subgroup of the digestive system cancer and urinary system cancer, but not in oral cavity cancers. Since Zou et al. 31 for the first time reported a significant association of pTEN rs701848 with laryngo cancer risk in 2006, more evidences have accumulated regarding the relationship between SNP rs701848 and the risk of various cancers, such as lung cancer 35 , esophageal cancer [37] [38] [39] 41 , breast cancer 27 , prostate cancer 15 , hepatocellular cancer 36 , renal cancer 7, 23 , gastric cancer 42 , and colorectal cancer 40 . It should be noted that SNP rs701848 is located within the 3′ near gene region, which can be targeted by microRNAs to affecting the miRNA binding site activity, thereby altering pTEN expression by influencing the mRNA stability, and then influence cancer susceptibility. However, the hypothesized function about SNP rs701848 still needs to be investigated in future studies and updated meta-analysis. AKT1 rs2494750, rs2494752 and cancer risk. In this pooled meta-analysis, 6 studied of 4332 cases and 4498 controls for rs2494750 polymorphism 7,15,23-27 and 3 studied of 3187 cases and 3174 controls for rs2494752 polymorphism 19, 26, 27 were included. A significant association was observed between rs2494752 and overall cancer risk, the heterozygous genotype AG, GG/AG genotype and G allele of rs2494752 SNP was associated with increased cancer risk. However, we have not found the correlation between rs2494750 polymorphism and the cancer susceptibility both in overall analysis and the stratification analysis. Previous study reported 15 that the risk effect of rs2494752 AG/GG genotypes was more obvious in the patients of ever-drinkers. Another investigation showed inconsistent results in alcohol consumption patients and risk of gastric cancer 25 . These results indicated that the environmental factors were interacted with the genetic variants in the aspect of carcinogenesis. Most importantly, the SNP rs2494752 is located at the 5′ UTR of AKT1 gene, a region predicted to be the transcription factor binding region based on the sequence alignments, which may affect the transcription and translation of AKT1. It is plausible that the rs2494752 G allele increased the transcription activity of the promoter in the AKT1 gene, then facilitated the cancer development and progression, which may partially explain the cancer risk associated with this SNP. However, the potential function of this SNP should be necessary to identify in larger sample studies in the future.
There is not previously reported meta-analysis to date that comprehensively elucidated the association between the five SNPs of the pTEN/AKT/mTOR signaling pathway and risk of cancer. However, some limitations need to be addressed in this meta-analysis. First, only Asian population was involved, lack of the samples of other ethnicities such as Caucasian, African in this study, thus a wider spectrum of subjects should be conducted on various ethnicities in the future. Second, only 3 studies were included for the SNP rs2494752, therefore considering the limited small size of rs2494752, we cannot rule out the possibility that the results may be by chance, although the number of study participants met the requirement for analysis. Third, all studies included in the present systematic review were reported in Chinese or English, yet other languages publications may include the relevant studies, which may be the main source of publication bias in our meta-analysis. Finally, only five SNPs located in the 3′UTR or 5′UTR of the candidate genes were chosen, however, the SNPs of exon or intron region was not included. Thus, the limited SNPs were not sufficient to capture most genetic information of pTEN/AKT/ mTOR signaling pathway, more SNPs should be included in the study, and interaction with others genes should be investigated in the future updated meta-analysis.
In conclusion, this meta-analysis was performed included the latest publications, and provided a more precise prevalence estimate for associations of five SNPs of pTEN/AK/mTOR pathway with the risk of cancer. We found that mTOR rs2295080 TG, GG genotype and GG/TG genotype carriers showed an decreased in the overall cancer risk, urinary system cancer and digestive system cancer, nevertheless TT genotype of rs2295080 was associated with increased the risk of blood system cancer. Carrying rs701848 CC,TC genotype and CC/TC genotype were associated with an increased overall cancer risk, especially in digestive system cancer and urinary system cancer. Moreover, a significant increased association was observed between rs2494752 AG and GG/AG genotype and overall cancer risk. Therefore, this present study provides the most valid cancer prevalence estimate to date for Asian population, which is a necessary foundational piece for further research on this topic.
Novelty and Impact Statements. In this meta-analysis of Asian population, the carriers of mTOR rs2295080 TG, GG genotype and GG/TG genotypes showed a significantly decreased the risk of overall cancer, the urinary system cancer and digestive system cancer. Furthermore, the SNP rs701848 CC, TC genotype and CC/TC genotype of pTEN were observed increased susceptibility of overall cancer and the subgroup of the urinary and digestive cancer. Moreover, carrying AKT1 rs2494752 AG and GG/AG genotypes showed an increased overall cancer risk.
